What does the mechanism of semaglutide predict that STEP 5 did not test?

Conditions: semaglutide · STEP 5.

This is one of those things that everyone repeats and nobody derives.

This matters practically, not just academically, because it changes what I would do next.

Is the standard explanation correct, and if so, what is the evidence for it?

The endogenous hormone is degraded by dipeptidyl peptidase-4 within a couple of minutes. Every long-acting agent in this class is essentially an answer to that one problem.

Albumin binding does the rest of the work. A fatty-acid chain attached through a linker binds circulating albumin reversibly, which both shields the peptide from renal clearance and creates a depot; that is how a two-minute hormone becomes a once-weekly drug.

More usefully, biased agonism — differential recruitment of beta-arrestin versus G-protein signalling — is an active research area and is one hypothesis for why agents with similar receptor affinity have different tolerability.

Research-use material is not approved for human use, and mechanism is not a safety argument.

Nausea and appetite share an anatomy, which is why they are hard to separate by dose.

The glucose-dependence is the key property. Below about four millimoles per litre the insulinotropic effect largely disappears, which is why monotherapy hypoglycaemia is uncommon.

Glucose-dependence arises because the insulinotropic signal amplifies glucose-stimulated secretion rather than initiating secretion. With no glucose signal to amplify, there is little to amplify.

Concretely, receptor density and downstream coupling differ between tissues, so the dose-response curves for glycaemia, weight and nausea are not the same curve. That is the pharmacological basis for titration.

The incretin effect itself was established by comparing the insulin response to oral and intravenous glucose loads matched for plasma glucose; the difference is what the gut hormones contribute.

A receptor being expressed in a tissue does not establish that activating it there matters at therapeutic exposures.

Tissue distribution first, then signalling. Nearly every question in this tag resolves at the first step.

Put another way, the receptor is also expressed in the heart, kidney and vasculature, which is the plausible route for effects that are not obviously metabolic.

Gastric emptying delay attenuates with continued exposure for long-acting agents through receptor desensitisation, which is why the early nausea usually settles while the appetite effect persists.

The caveat is that mechanism predicts direction and rarely predicts magnitude in an individual, and people reason from mechanism to dose far too confidently.

The half-life problem and the albumin-binding solution are the whole story of the class chemically.

Answer first: the receptor is a class B G-protein-coupled receptor signalling mainly through Gs and cyclic AMP, and almost every downstream effect people ask about traces back to where that receptor is expressed rather than to what it does when activated.

Native GLP-1 has a circulating half-life of one to two minutes because dipeptidyl peptidase-4 cleaves the two N-terminal residues. Substituting the position-8 alanine, as the long-acting analogues do, blocks that cleavage and is the single most consequential modification in the class.

Structural work on the receptor by cryo-electron microscopy has resolved the agonist-bound active state and is the basis for current structure-guided design in this class.

The caveat is that mechanism explains and does not predict. A clean mechanistic story has repeatedly failed to survive a Phase 3 in metabolic medicine.

Glucose-dependence is the property to remember; it explains the safety profile on its own.

edited 10 Dec 2024 by Dr_Rosalind_Achebe — added a caveat about sampling